Folliculitis Decalvans Due to Epidermal Growth Factor Inhibitor

Aurora Maria Alessandrini; Alice Nadia Rossi; Emi Dika

doi:10.5826/dpc.1403a161

Folliculitis Decalvans Due to Epidermal Growth Factor Inhibitor

Authors

Aurora Maria Alessandrini Dermatology, Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, Bologna, Italy
Alice Nadia Rossi Dermatology, Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, Bologna, Italy
Emi Dika IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

Keywords:

dermatologic drug adverse effects, EGFR inhibitor, trichology

References

Fernández-Domper L, Ballesteros-Redondo M, Vañó-Galván S. Trichoscopy: An Update. Actas Dermosifiliogr. 2023 Apr;114(4):327-333. English, Spanish.

Bardazzi F, Savoia F, Parente G, Tabanelli M, Balestri R, Spadola G, Dika E. Azithromycin: a new therapeutical strategy for acne in adolescents. Dermatol Online J. 2007 Oct 13;13(4):4.

Lacouture ME, Wainberg ZA, Patel AB, et al. Reducing skin toxicities from egfr inhibitors with topical braf inhibitor therapy. Cancer Discov. 2021;11(9):2158-2167.

Dervout C, Chiappa A-M, Fleuret C, Plantin P, Acquitter M. Alopécie cicatricielle à type de folliculite décalvante induite par l’erlotinib. Ann Dermatol Venereol. 2020;147(12):848-852.

Osimertinib tablets. United States Prescribing Information. US National Library of Medicine. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf (Accessed on August 26, 2019).

Philpott MP, Kealey T. Effects of EGF on the morphology and patterns of DNA synthesis in isolated human hair follicles. J Invest Dermatol. 1994 Feb;102(2):186-91. doi: 10.1111/1523-1747.ep12371760. PMID: 8106747.